HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC
Question
HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC
Direct answer
HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics. — bullish pressure on AZN.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-31
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC”, revision 1, evidence through 2026-08-31. https://marketontology.com/catalysts/2026-08-31/hutchmed-and-astrazeneca-announce-positive-phase-iii-sanovo-trial-in-nsclc-faefff
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| AZN | ▲Bull | 1–4 weeks | Policy Shift | 69 |
HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLC
HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics. — bullish pressure on AZN.
HUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics.
- SummaryHUTCHMED announced top-line findings from the Phase III SANOVO clinical study evaluating ORPATHYS (savolitinib) in combination with AstraZeneca's TAGRISSO (osimertinib). The regimen achieved a statistically significant improvement in progression-free survival among treatment-naive Chinese patients diagnosed with MET-overexpressing, EGFR-mutated non-small cell lung cancer, alongside supportive overall survival metrics.
- AZNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AZN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AZN price vs. pre-event level
- AZN volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.